{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T22:27:09Z","timestamp":1774304829839,"version":"3.50.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2018,4,17]]},"abstract":"<jats:sec xml:lang=\"en\">\n            <jats:title>Background<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              Mineralocorticoid receptor antagonist (\n              <jats:styled-content style=\"fixed-case\">MRA<\/jats:styled-content>\n              ) therapy may be beneficial to patients with atrial fibrillation (\n              <jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content>\n              ), but little is known about their use in patients with\n              <jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content>\n              and subsequent outcomes.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Methods and Results<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              In order to better understand\n              <jats:styled-content style=\"fixed-case\">MRA<\/jats:styled-content>\n              use and subsequent outcomes, we performed a retrospective cohort study of the contemporary\n              <jats:styled-content style=\"fixed-case\">ORBIT<\/jats:styled-content>\n              \u2010\n              <jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content>\n              (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) registry.\n              <jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content>\n              progression and cardiovascular outcomes were compared using propensity\u2010matched Cox proportional hazards modeling according to\n              <jats:styled-content style=\"fixed-case\">MRA<\/jats:styled-content>\n              use at baseline and new\n              <jats:styled-content style=\"fixed-case\">MRA<\/jats:styled-content>\n              use at follow\u2010up versus patients with no\n              <jats:styled-content style=\"fixed-case\">MRA<\/jats:styled-content>\n              use. Among 7012 patients with nonpermanent\n              <jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content>\n              , 320 patients were taking\n              <jats:styled-content style=\"fixed-case\">MRA<\/jats:styled-content>\n              at enrollment, and 416 patients initiated\n              <jats:styled-content style=\"fixed-case\">MRA<\/jats:styled-content>\n              use during follow\u2010up. The mean patient age was 72.5\u00a0years, 56.3% were men, and 70.4% had paroxysmal\n              <jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content>\n              . Among all patients taking\n              <jats:styled-content style=\"fixed-case\">MRAs,<\/jats:styled-content>\n              434 (59.0%) had heart failure, 655 (89.0%) had hypertension, and 380 (51.6%) had both. After adjustment, new\n              <jats:styled-content style=\"fixed-case\">MRA<\/jats:styled-content>\n              use was not associated with reduced\n              <jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content>\n              progression (hazard ratio, 1.18; 95% confidence interval, 0.88\u20131.58;\n              <jats:italic>P<\/jats:italic>\n              =0.27) but showed a trend towards lower risk of stroke, transient ischemic attack, or systemic embolism (hazard ratio, 0.17; 95% confidence interval, 0.02\u20131.23;\n              <jats:italic>P<\/jats:italic>\n              =0.08). Results were similar for a comparison of new\n              <jats:styled-content style=\"fixed-case\">MRA<\/jats:styled-content>\n              users and baseline\n              <jats:styled-content style=\"fixed-case\">MRA<\/jats:styled-content>\n              users compared with nonusers.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              In community\u2010based outpatients with\n              <jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content>\n              , the majority of\n              <jats:styled-content style=\"fixed-case\">MRA<\/jats:styled-content>\n              use was for\n              <jats:styled-content style=\"fixed-case\">heart failure<\/jats:styled-content>\n              and hypertension.\n              <jats:styled-content style=\"fixed-case\">MRA<\/jats:styled-content>\n              use also trended towards lower adjusted stroke risk. Future studies should test the hypothesis that\n              <jats:styled-content style=\"fixed-case\">MRA<\/jats:styled-content>\n              use may decrease the risk of stroke in patients with\n              <jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content>\n              .\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/jaha.117.007987","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T09:20:13Z","timestamp":1523611213000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBIT\u2010AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry"],"prefix":"10.1161","volume":"7","author":[{"given":"Marat","family":"Fudim","sequence":"first","affiliation":[{"name":"Division of Cardiology, Duke Clinical Research Institute, Durham, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter R.","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke Clinical Research Institute, Durham, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Shrader","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke Clinical Research Institute, Durham, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalia G.","family":"Blanco","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke Clinical Research Institute, Durham, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry A.","family":"Allen","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine, Aurora, CO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[{"name":"Ronald Reagan\u2010UCLA Medical Center, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard J.","family":"Gersh","sequence":"additional","affiliation":[{"name":"Mayo Clinic College of Medicine Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter R.","family":"Kowey","sequence":"additional","affiliation":[{"name":"Lankenau Institute for Medical Research, Wynnewood, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Palo Alto, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Hylek","sequence":"additional","affiliation":[{"name":"Boston University School of Medicine, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan S.","family":"Go","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northern California, Oakland, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laine","family":"Thomas","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke Clinical Research Institute, Durham, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric D.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke Clinical Research Institute, Durham, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan P.","family":"Piccini","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke Clinical Research Institute, Durham, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.08.022"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.177292"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/1074248415619490"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e3182a094a1"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.02.009"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.03.021"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08090-X"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7339.699"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06178-5"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx739"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.03.063"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.64.1.9"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.09.045"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2004.04.013"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2010.07.037"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.12.020"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eup321"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.11.063"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2006.11.015"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.07.001"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2014-307043"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.10.068"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2007.01780.x"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.107128"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.20914"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.117.007987","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T11:22:24Z","timestamp":1715599344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.117.007987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,17]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,4,17]]}},"alternative-id":["10.1161\/JAHA.117.007987"],"URL":"https:\/\/doi.org\/10.1161\/jaha.117.007987","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,17]]},"assertion":[{"value":"2017-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e007987"}}